Here at the Bioprocessing International European Summit, we asked a number of leading industry experts from across all sectors of the industry what are the biggest challenges they are currently facing in their work, and what is being done to resolve and overcome these challenges.
Parrish Galliher, Chief Technology Officer for Upstream, GE Healthcare outlines his thoughts on current challenges.
“Well certainly in the downstream area there are additional challenges compared to the upstream. In the upstream, the consensus is that continuous bioprocessing and purification is more straight forward than in the downstream and there is less debate about the cost benefits of continuous chromatography for example. There is a pretty consistent report in the industry around the globe that continuous chromatography can afford reduced quantities of resin required and therefore reduced quantity of buffer required. Being a more straight forward system with far fewer parameters and variables compared to upstream the complexity of continuous downstream processing seems to be reduced compared to upstream.
So the ability to deploy it and to scale it out and to transfer it to manufacturing settings and environments is predicted to be easier. Continuous chromatography has been around for a long time in the small molecule industry, so in itself is not new technology, but for biopharmaceuticals it’s obviously new and has new application and we will see over the next five to ten years how well it progresses from the laboratory and pilot scale into the commercial sector.”
Parrish Galliher is joined by a number of experts from across all sectors of the industry in the short film below.